Moreno F, Cacciavillano W, Cipolla M, Coirini M, Streitenberger P, López Martí J, Palladino M, Morici M, Onoratelli M, Drago G, Schifino A, Cores M, Rose A, Jotomliansky J, Varel M, García Lombardi M
Argentinian Oncopediatric Registry, National Cancer Institute, Ministry of Health, Buenos Aires, Argentina.
Garrahan Pediatric Hospital, Buenos Aires, Argentina.
Pediatr Blood Cancer. 2017 Oct;64(10). doi: 10.1002/pbc.26533. Epub 2017 Apr 14.
Differences in incidence and survival in osteosarcoma reports are considerable worldwide.
This study describes the incidence and survival of patients with osteosarcoma in Argentina with data from the National Pediatric Cancer Registry (ROHA), and the impact of age, gender, stage, regional, and socioeconomic indicators on outcome.
Pediatric patients with osteosarcoma reported to ROHA from 2000 through 2013 were analyzed, the annual age-standardized incidence rate (ASR) was calculated using the National Vital Statistics, and survival was estimated. The extended human development index (EHDI) for each reporting region was used as an indicator of socioeconomic status.
There were 515 cases of osteosarcoma identified, yielding an ASR of 3.2/1,000,000 children (0-14 years old). The ASR did not vary significantly by year of diagnosis but ranged from 4.0/1,000,000 in the Cuyo/Western Central region to 2.7/1,000,000 in the northeast region (P < 0.000). The estimated 5-year survival rate was 45% (95% confidence interval [CI] 44-51%), with no difference by sex, diagnosis year, region, or EHDI score (P > 0.1 in all cases). Survival rate for localized disease was 52% (95% CI 45-57%) and for metastatic 22% (95% CI 15-30%).
In Argentina, ASR of osteosarcoma is similar to that in high-income countries, but survival is lower in all regions. Future work will focus on identification and reduction of causes of preventable treatment failure.
全球范围内骨肉瘤报告中的发病率和生存率差异很大。
本研究利用国家儿科癌症登记处（ROHA）的数据描述阿根廷骨肉瘤患者的发病率和生存率，以及年龄、性别、分期、地区和社会经济指标对预后的影响。
分析2000年至2013年向ROHA报告的骨肉瘤儿科患者，使用国家生命统计数据计算年度年龄标准化发病率（ASR），并估计生存率。每个报告地区的扩展人类发展指数（EHDI）用作社会经济地位指标。
共确定515例骨肉瘤病例，0至14岁儿童的ASR为3.2/1,000,000。ASR在诊断年份之间无显著差异，但在库约/中西部地区为4.0/1,000,000，在东北地区为2.7/1,000,000（P<0.000）。估计5年生存率为45%（95%置信区间[CI]44-51%），性别、诊断年份、地区或EHDI评分均无差异（所有情况下P>0.1）。局限性疾病的生存率为52%（95%CI 45-57%），转移性疾病为22%（95%CI 15-30%）。
在阿根廷，骨肉瘤的ASR与高收入国家相似，但所有地区的生存率较低。未来的工作将集中于识别和减少可预防治疗失败的原因。
